A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy

Huang, Li; Che, Zhang; Gu, Jiaowei; Wu, Wei; Shen, Zhujun; Zhou, Xihui; Lü, Haixia

doi:10.1177/0963689717729379

Cited by 94 publications

(106 citation statements)

References 34 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Human umbilical cord-blood derived MSCs have fewer ethical issues in comparison to rehabilitation [38]. Compared to other MSCs, they have a low immunogenicity; for example, hUCB-MSCs not only have a lower immunogenicity than bone marrowderived MSCs, but they also have higher proliferative capacity and stronger immunosuppressive potential [38]. Allogeneic (derived from a matching donor or external cell source) hUCB-MSCs can maintain a low immunogenicity in vitro and in vivo, suggesting the safety of using them in allogeneic clinical applications [38].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Compared to other MSCs, they have a low immunogenicity; for example, hUCB-MSCs not only have a lower immunogenicity than bone marrowderived MSCs, but they also have higher proliferative capacity and stronger immunosuppressive potential [38]. Allogeneic (derived from a matching donor or external cell source) hUCB-MSCs can maintain a low immunogenicity in vitro and in vivo, suggesting the safety of using them in allogeneic clinical applications [38]. It has also been concluded that hUCB-MSCs could be efficaciously transplanted even when they were major histocompatibility complex mismatched [38].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Allogeneic (derived from a matching donor or external cell source) hUCB-MSCs can maintain a low immunogenicity in vitro and in vivo, suggesting the safety of using them in allogeneic clinical applications [38]. It has also been concluded that hUCB-MSCs could be efficaciously transplanted even when they were major histocompatibility complex mismatched [38]. Moreover, cells from umbilical cord blood can tolerate more human leukocyte antigen-mismatches without rejection, possibly due to the immature fetal immune system [33].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 3 more Smart Citations

Untitled

2020

JSCR

View full text Add to dashboard Cite

As the gestational age at birth decreases, the risk of the infant having CP increases [6]. Detections of CP among premature births are mostly found through white matter damage on brain-imaging modalities [6]. Evidence of single or multiple brain lesions or ventriculomegaly in a pre-term infant leads to a 50% risk of developing CP [6]. The prenatal Abstract Cerebral palsy (CP) is a neurodevelopmental disorder that hinders normal motor activity and muscle coordination. CP typically appears before, during, or soon after birth as the brain is still developing. The severity of this multifactorial condition depends on the damage done to the parts of the brain that control muscle tone and body movement. The insult in the underdeveloped brain prohibits normal growth; neurons and oligodendrocytes will either die or fail to develop, and the white matter tracts that connect various brain regions become malfunctional. Cerebral palsy is classified into different types depending on the areas of the brain that were insulted and the nature of the movement disorder: spasticity, dyskinesia, and ataxia. Abnormal brain development in patients with CP cannot be reversed, but various treatments are shown to improve and normalize the symptoms. Stem cell transplantation, a regenerative therapy that can replace the damaged and non-functional cells of the brains in CP patients, has shown effective results. Embryonic stem cells (ESC), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), human amnion epithelial cells (hAEC), and neural stem cells (NSC) are infused to reproduce into more specialized cell types. This alternative therapeutic method has shown successful results through preclinical animal research and clinical trials.

show abstract

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

2020

JSCR

View full text Add to dashboard Cite

show abstract

“…There is currently no specific treatment for CP except for rehabilitation training in the clinic (Maclennan et al, ). Since the first transplantation of UCBCs was performed in 1988 (Mreboredo, Diaz, Castro, & Villaescusa, ), UCB‐SC therapy has been widely studied in children with CP, and improved brain cognition and gross motor function have been shown with no serious side effects indicating that the therapy is neuroprotective and safe (Feng et al, ; Huang et al, ; Kang et al, ; Lee et al, ; Min et al, ; Romanov et al, ; Sun et al, ) (Table ). However, current clinical trials focused on UCB‐SC therapy in children with CP have not considered the gestational age partition of the patients, and thus further research is needed regarding children with CP who were born prematurely.…”

Section: Ucb‐sc Therapy In Preterm Brain Injuries and Neurological Sementioning

confidence: 99%

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Peng

Shi

et al. 2019

J of Neuroscience Research

View full text Add to dashboard Cite

Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)‐derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB‐derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB‐derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.

show abstract

Using umbilical cord blood for regenerative therapy: Proof or promise?

Allan

2020

Stem Cells

View full text Add to dashboard Cite

The identification of nonhematopoietic progenitor cells in cord blood has spawned great interest in using cord blood cells for new indications in regenerative therapy.Many preclinical studies demonstrated improvement in reperfusion and markers of organ recovery using cord blood-derived cells in a range of animal models. Initial results heralded increasing clinical interest regarding the use of cord blood for regenerative therapy. Initial clinical studies were largely uncontrolled feasibility studies that were case series and reported on small numbers of patients. The emergence of controlled studies has been slower, although multiple controlled studies have been conducted in patients with cerebral palsy and type I diabetes. Heterogeneity in the cellular product, patients, study design, and the timing of outcome measurements remains barriers to meta-analysis and a clearer understanding of efficacy. Controlled studies of modest size have been reported for a range of additional conditions. The conduct of controlled clinical trials to evaluate potential new uses of cord blood for regenerative therapy remains essential. None of the indications studied to date can be regarded as proven. Moreover, consistency in outcome reporting in terms of the instruments used and the time points for assessment after therapy are needed, including longer follow-up of study participants. Frequent and careful evaluation of the evidence will allow cord blood banks, health care providers, and patients to assess potential new options in the use of cord blood for regenerative therapy. K E Y W O R D S clinical trial, cord blood, regenerative therapy

show abstract

A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy

Cited by 94 publications

References 34 publications

Untitled

Untitled

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Using umbilical cord blood for regenerative therapy: Proof or promise?

Contact Info

Product

Resources

About